Rocuronium Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414624

CAS#: 143558-00-3 (free base)

Description: Rocuronium Free Base is an androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM.

Chemical Structure

img
Rocuronium Free Base
CAS# 143558-00-3 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 414624
Name: Rocuronium Free Base
CAS#: 143558-00-3 (free base)
Chemical Formula: C32H53N2O4+
Exact Mass: 529.40
Molecular Weight: 529.790
Elemental Analysis: C, 72.55; H, 10.08; N, 5.29; O, 12.08

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 143558-00-3 (free base); 119302-91-9 (bromide)  

Synonym: Rocuronium Free Base; ORG9426; ORG-9426; ORG 9426

IUPAC/Chemical Name: 1-((2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetoxy-3-hydroxy-10,13-dimethyl-2-morpholinohexadecahydro-1H-cyclopenta[a]phenanthren-16-yl)-1-allylpyrrolidin-1-ium

InChi Key: YXRDKMPIGHSVRX-OOJCLDBCSA-N

InChi Code: InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1

SMILES Code: CC(O[C@H]1[C@@H]([N+]2(CCCC2)CC=C)C[C@H]3[C@@H]4CC[C@H]5C[C@@H]([C@@H](N6CCOCC6)C[C@@]5([C@H]4CC[C@]13C)C)O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 529.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Guihard B, Chollet-Xémard C, Lakhnati P, Vivien B, Broche C, Savary D, Ricard-Hibon A, Marianne Dit Cassou PJ, Adnet F, Wiel E, Deutsch J, Tissier C, Loeb T, Bounes V, Rousseau E, Jabre P, Huiart L, Ferdynus C, Combes X. Effect of Rocuronium vs Succinylcholine on Endotracheal Intubation Success Rate Among Patients Undergoing Out-of-Hospital Rapid Sequence Intubation: A Randomized Clinical Trial. JAMA. 2019 Dec 17;322(23):2303-2312. doi: 10.1001/jama.2019.18254. PMID: 31846014; PMCID: PMC6990819.

2: Tran DTT, Newton EK, Mount VAH, Lee JS, Mansour C, Wells GA, Perry JJ. Rocuronium vs. succinylcholine for rapid sequence intubation: a Cochrane systematic review. Anaesthesia. 2017 Jun;72(6):765-777. doi: 10.1111/anae.13903. PMID: 28654173.

3: Liu XW, Gong RS, Liu Z, Zuo J, Zhao J. [Neuromuscular Pharmacodynamics of Rocuronium in Diabetic Rats]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019 Apr 28;41(2):149-155. Chinese. doi: 10.3881/j.issn.1000-503X.11169. PMID: 31060667.

4: Swaminathan AK, Mallemat H. Rocuronium Should Be the Default Paralytic in Rapid Sequence Intubation. Ann Emerg Med. 2018 Mar;71(3):397-398. doi: 10.1016/j.annemergmed.2017.04.039. Epub 2017 Jun 23. PMID: 28601274.

5: Murata Y, Kawamoto S, Fukuda K. Rocuronium Has a Suppressive Effect on Platelet Function via the P2Y12 Receptor Pathway In Vitro That Is Not Reversed by Sugammadex. Int J Mol Sci. 2020 Sep 3;21(17):6399. doi: 10.3390/ijms21176399. PMID: 32899133; PMCID: PMC7504164.

6: Bebawy JF. Rocuronium bromide. Anesthesiology. 2011 Jun;114(6):1486. doi: 10.1097/ALN.0b013e3181fe3cea. PMID: 21263302.

7: Long CS, Miller MR, McMullin GM, Tivey SL. Transesophageal Echocardiography- Guided Cardiopulmonary Resuscitation After Rocuronium Anaphylaxis. A A Pract. 2020 Apr;14(6):e01175. doi: 10.1213/XAA.0000000000001175. PMID: 32132360.

8: Couto M, Nunes C, Vide S, Amorim P, Mendes J. Rocuronium Continuous Infusion for Profound Neuromuscular Blockade: A Systematic Review and Meta-analysis. Clin Neuropharmacol. 2019 Nov/Dec;42(6):203-210. doi: 10.1097/WNF.0000000000000366. PMID: 31725475.

9: Tachikawa M, Asai T, Okuda Y. Rocuronium Bromide Intravenous Solution Maruishi® is more suitable than ESLAX Intravenous® during rapid-sequence induction of anesthesia. J Anesth. 2019 Oct;33(5):600-603. doi: 10.1007/s00540-019-02673-x. Epub 2019 Aug 21. PMID: 31435739.

10: Zhu XY, Xue FS, Shao LJ, Li XL. Comparing Succinylcholine and Rocuronium for Emergency Intubation. Ann Emerg Med. 2019 May;73(5):548-549. doi: 10.1016/j.annemergmed.2018.12.003. PMID: 31029292.